New progress in the study of Asprosin

doi:10.3969/j.issn.1009-976X.2022.02.018

Abstract

Abstract: Asprosin is a new kind of glycogen adipokines, which is synthesized and released by white adipose tissue mainly in fasting. Asprosin plays a complex role in the central nervous system, peripheral tissues and organs. It is associated with appetite, glucose metabolism, insulin resistance （IR）, apoptosis and so on. Recent studies have found that Asprosin plays an important and complex role in metabolic and metabolic diseases. Metabolic diseases mainly include diabetes mellitus （DM）, nonalcoholic fatty liver disease （NAFLD）, polycystic ovarian syndrome （PCOS）, and cardiovascular diseases. It is mainly due to the destruction of normal metabolic processes. At present, such diseases bring a great threat to human health and the quality of life. In this paper, we reviewed the progress of asprosin in metabolic diseases in recent years, and provided new ideas for clinical diagnosis and treatment in the future.

Key words: asprosin, metabolic diseases, diabetes mellitus, nonalcoholic fatty liver disease, polycystic ovarian syndrome

摘要： 白脂素（Asprosin）是一种新的糖原性脂肪因子,主要在空腹时由白色脂肪组织合成并释放。Asprosin在中枢神经系统、外周组织和器官中起着复杂的作用。它与食欲、糖代谢、胰岛素抵抗（IR）、细胞凋亡等有关。最近的研究发现,Asprosin在代谢和代谢性疾病中起着重要而复杂的作用。代谢性疾病,主要包括糖尿病（DM）、非酒精性脂肪肝（NAFLD）、多囊卵巢综合征（PCOS）、心血管疾病,其主要是由于正常代谢过程的破坏。目前,这类疾病对人类健康和生命质量构成巨大威胁。本文就近年来发现的阿司匹林在代谢性疾病中的相关进展作一综述,为今后的临床诊疗提供新思路。

关键词: 白脂素, 代谢性疾病, 糖尿病, 非酒精性脂肪肝, 多囊卵巢综合征

CLC Number:

XUE Jia-jing, GUO Wei, ZHAO Bing-bing, ZHAO Ling-fei. New progress in the study of Asprosin[J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 210-213.

薛佳婧, 郭伟, 赵兵兵, 赵凌飞. 白脂素的研究进展[J]. 岭南现代临床外科, 2022, 22(02): 210-213.

References

[1] Romere C, Duerrschmid C, Bournat J, et al.Asprosin, a Fasting-Induced Glucogenic Protein Hormone[J]. Cell, 2016, 165(3): 566-579.
[2] O′Neill B, Simha V, Kotha V, et al. Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome[J]. Am J Med Genet A, 2007, 143A(13): 1421-1430.
[3] 胡芬, 张运峰. Fc-Asprosin融合蛋白表达及糖尿病患者血清Asprosin水平检测[J]. 基因组学与应用生物学, 2018, 37(8): 3647-3651.
[4] Rautenstrauch T, Snigula F.Progeria: a cell culture study and clinical report of familial incidence[J]. Eur J Pediatr, 1977, 124(2): 101-111.
[5] Naiemian S, Naeemipour M, Zarei M, et al.Serum concentration of asprosin in new-onset type 2 diabetes[J]. Diabetol Metab Syndr, 2020, 12: 65.
[6] Zhang L, Chen C, Zhou N, et al.Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride[J]. Clin Chim Acta, 2019, 489: 183-188.
[7] 刘师伟, 吴亚茹, 段瑞雪, 等. 2型糖尿病患者血清Asprosin水平及其与代谢指标的相关性研究[J]. 重庆医科大学学报, 2018, 43(12): 1613-1618.
[8] Wang YR, Qu H, Xiong X, et al.Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion[J]. Mediators Inflamm, 2018, 2018: 9471583.
[9] Gozel N, Kilinc F.Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin[J]. Endokrynol Pol,2021, 72(1): 37-43.
[10] Zhang HY, Hu WQ, Zhang G.Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease[J]. Int Urol Nephrol, 2020, 52(8): 1517-1522.
[11] Deng X, Zhao L, Guo C, et al.Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes[J]. Diabetes Metab Syndr Obes, 2020, 13: 4341-4351.
[12] Cho NH, Shaw JE, Karuranga S, et al.IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138: 271-281.
[13] 朱丽雯, 谭延振, 罗文平, 等. Asprosin的表达纯化及其对小鼠在体心脏功能的作用[J]. 中国实验动物学报, 2017, 25(4): 368-372.
[14] Jia G, Whaley-Connell A, Sowers JR.Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease[J]. Diabetologia, 2018, 61(1): 21-28.
[15] 冯健, 杜劲, 侯娟妮, 等. 白脂素对高糖导致的心肌细胞损伤保护作用的研究[J]. 中国糖尿病杂志, 2018, 26(9): 775-779.
[16] 陈莎, 汪雄, 邱琛茗, 等. Spartin和白脂素在糖尿病心脏微血管内皮损伤中的作用及其机制探讨[J]. 四川大学学报(医学版), 2019, 50(6): 827-834.
[17] Ke F, Xue GH, Jiang XL, et al.Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease[J]. Cytokine, 2020, 134:155184.
[18] 贾素红, 凌莉, 朱维培, 等. 具有多囊卵巢综合征表型绝经女性心血管疾病发病风险研究[J]. 中国实用妇科与产科杂志, 2016, 32(9): 873-876.
[19] Dunaif A.Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis[J]. Endocr Rev, 1997, 18(6): 774-800.
[20] Li X, Liao MY, Shen RF, et al.Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases[J]. Mediators Inflamm, 2018, 2018: 7375294.
[21] Alan M, Gurlek B, Yilmaz A, et al.Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2019, 35(3): 220-223.
[22] Chang CL, Huang SY, Hsu YC, et al.The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients[J]. Sci Rep, 2019, 9(1): 6447.
[23] Sahay N, Bhalotra A, Saini G, et al.Anesthesia in an Aging Infant: Neonatal Progeroid Syndrome[J]. A A Case Rep, 2015, 5(10): 173-175.
[24] 徐佰达, 叶挺, 王倩, 等. 血浆白脂素水平与冠心病的关系[J]. 心脏杂志, 2019,31(04): 428-431.
[25] Wen MS, Wang CY, Yeh JK, et al.The role of Asprosin in patients with dilated cardiomyopathy[J]. BMC Cardiovasc Disord, 2020, 20(1): 402.